×
About 20,492 results

ALLMedicine™ Hypercholesterolemia Center

Research & Reviews  8,323 results

Investigation of the underlying genes and mechanism of familial hypercholesterolemia th...
https://doi.org/10.1186/s12872-020-01701-z
BMC Cardiovascular Disorders; Wang D, Liu B et. al.

Sep 17th, 2020 - Familial hypercholesterolemia (FH) is one of the commonest inherited metabolic disorders. Abnormally high level of low-density lipoprotein cholesterol (LDL-C) in blood leads to premature atherosclerosis onset and a high risk of cardiovascular dise...

Effect of Lactobacillus plantarum HT121 on serum lipid profile, gut microbiota, and liv...
https://doi.org/10.1016/j.nut.2020.110966
Nutrition (Burbank, Los Angeles County, Calif.); Li X, Xiao Y et. al.

Sep 17th, 2020 - The aim of this study was to evaluate effect of Lactobacillus plantarum HT121 on serum lipid profile, gut microbiota, and liver transcriptome and metabolomics. L. plantarum HT121 was selected by screening of acid and bile salt tolerance and choles...

ANNALS EXPRESS: Homozygous autosomal recessive hypercholesterolaemia in a South Asian c...
https://doi.org/10.1177/0004563220961755
Annals of Clinical Biochemistry; Thadchanamoorthy V, Dayasiri K

Sep 16th, 2020 - Autosomal recessive hypercholesterolemia (ARH; OMIM #603813) is an extremely rare disorder of lipid metabolism caused by loss-of-function mutations in the LDL receptor adapter protein 1 (LDLRAP1) gene, which is characterised by severe hypercholest...

Familial hypercholesterolemia: A single-nucleotide variant (SNV) in mosaic at the low d...
https://doi.org/10.1016/j.atherosclerosis.2020.08.002
Atherosclerosis Rodríguez-Nóvoa S, Rodríguez-Jiménez C et. al.

Sep 16th, 2020 - Familial hypercholesterolemia is most frequently caused by genetic variants in the LDLR gene. Most of LDLR pathogenic variants are missense, followed by splicing and deletion/insertions variants. Mosaicism is a genetic condition in which an indivi...

Ineffective Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Monotherapy in Dyslipidemia with...
https://doi.org/10.12659/AJCR.923722
The American Journal of Case Reports; Matta A, Taraszkiewicz D et. al.

Sep 15th, 2020 - BACKGROUND Real-life data on the efficacy of monotherapy with PCSK9 inhibitors are scarce. Most cohort studies have examined populations that are not severely dyslipidemic and are receiving combined therapy rather than monotherapy. CASE REPORT Fro...

see more →

Guidelines  25 results

Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
https://esperion.gcs-web.com/node/11206/pdf

Feb 24th, 2020 - Esperion announced today that the U.S. Food and Drug Administration (FDA) approved NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. NEXLETOL is indicated as an adjunct to diet and maxima...

Statin Use and the Site-Specific Risk of Colorectal Cancer in Individuals with Hypercholesterolemia from the National Health Insurance Service-National Health Screening Cohort (NHIS-HEALS)
https://www.sciencedirect.com/science/article/pii/S0939475319301164?via%3Dihub
Nutrition, Metabolism and Cardiovascular Diseases; Lee,J.,et al

Apr 12th, 2019 - Background and Aims We investigated the association between statin use and site-specific risk of colorectal cancer in individuals with hypercholesterolemia. Methods and Results This study is based on the National Health Insurance Service-National...

Lipid levels and the risk of hemorrhagic stroke among women
https://n.neurology.org/content/early/2019/04/10/WNL.0000000000007454
Rist,P.,et al

Apr 9th, 2019 - Objective To examine the association between lipid levels and hemorrhagic stroke risk among women. Methods We performed a prospective cohort study among 27,937 women enrolled in the Women's Health Study with measured total cholesterol, low-densit...

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Up...
https://doi.org/10.1016/j.cjca.2018.09.005
The Canadian Journal of Cardiology; Brunham LR, Ruel I et. al.

Dec 11th, 2018 - Familial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are...

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of ...
http://www.onlinejacc.org/content/early/2018/11/02/j.jacc.2018.11.003
Grundy, S.,et al

Nov 9th, 2018 - The recommendations listed in the present guideline are, whenever possible, evidence based. An initial extensive evidence review, which included literature derived from research involving human subjects, published in English, and indexed in MEDLIN.

see more →

Drugs  1,643 results see all →

Clinicaltrials.gov  10,161 results

Investigation of the underlying genes and mechanism of familial hypercholesterolemia th...
https://doi.org/10.1186/s12872-020-01701-z
BMC Cardiovascular Disorders; Wang D, Liu B et. al.

Sep 17th, 2020 - Familial hypercholesterolemia (FH) is one of the commonest inherited metabolic disorders. Abnormally high level of low-density lipoprotein cholesterol (LDL-C) in blood leads to premature atherosclerosis onset and a high risk of cardiovascular dise...

Effect of Lactobacillus plantarum HT121 on serum lipid profile, gut microbiota, and liv...
https://doi.org/10.1016/j.nut.2020.110966
Nutrition (Burbank, Los Angeles County, Calif.); Li X, Xiao Y et. al.

Sep 17th, 2020 - The aim of this study was to evaluate effect of Lactobacillus plantarum HT121 on serum lipid profile, gut microbiota, and liver transcriptome and metabolomics. L. plantarum HT121 was selected by screening of acid and bile salt tolerance and choles...

ANNALS EXPRESS: Homozygous autosomal recessive hypercholesterolaemia in a South Asian c...
https://doi.org/10.1177/0004563220961755
Annals of Clinical Biochemistry; Thadchanamoorthy V, Dayasiri K

Sep 16th, 2020 - Autosomal recessive hypercholesterolemia (ARH; OMIM #603813) is an extremely rare disorder of lipid metabolism caused by loss-of-function mutations in the LDL receptor adapter protein 1 (LDLRAP1) gene, which is characterised by severe hypercholest...

Familial hypercholesterolemia: A single-nucleotide variant (SNV) in mosaic at the low d...
https://doi.org/10.1016/j.atherosclerosis.2020.08.002
Atherosclerosis Rodríguez-Nóvoa S, Rodríguez-Jiménez C et. al.

Sep 16th, 2020 - Familial hypercholesterolemia is most frequently caused by genetic variants in the LDLR gene. Most of LDLR pathogenic variants are missense, followed by splicing and deletion/insertions variants. Mosaicism is a genetic condition in which an indivi...

Simvastatin - simvastatin tablet, film coated-American Health Packaging
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51dd8d34-e660-49dc-a86e-07d031a18465

Sep 16th, 2020 - Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an a...

see more →

News  335 results

New lipid-lowering drug class slashes LDL in HoFH patients
https://www.mdedge.com/fedprac/article/219837/lipid-disorders/new-lipid-lowering-drug-class-slashes-ldl-hofh-patients?channel=53
Mitchel L. Zoler

Mar 30th, 2020 - Evinacumab, the first agent from a new class of lipid-lowering drugs, showed a “remarkable” and unprecedented level of LDL-cholesterol lowering in a pivotal trial with 65 patients with homozygous familial hypercholesterolemia. Dr.

Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
https://esperion.gcs-web.com/node/11206/pdf

Feb 24th, 2020 - Esperion announced today that the U.S. Food and Drug Administration (FDA) approved NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. NEXLETOL is indicated as an adjunct to diet and maxima...

New lipid-lowering drug earns FDA approval
https://www.mdedge.com/jcomjournal/article/217680/lipid-disorders/new-lipid-lowering-drug-earns-fda-approval?channel=39313
Patrice Wendling

Feb 21st, 2020 - The Food and Drug Administration has approved bempedoic acid (Nexletol) for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL cho.

Statins cut long-term CVD risk in kids with familial hypercholesterolemia
https://www.mdedge.com/internalmedicine/article/212063/lipid-disorders/statins-cut-long-term-cvd-risk-kids-familial?channel=39313
Andrew D. Bowser

Nov 11th, 2019 - Statins started in childhood for patients with familial hypercholesterolemia reduced progression of carotid thickening and cut the risk of cardiovascular disease 20 years later, according to authors of a long-term follow-up study. There were no de.

Aortic Stenosis in FH; Plaque Erosion; CAD Wave Intensity Analysis
https://www.medpagetoday.com/cardiology/pci/82923

Oct 24th, 2019 - Familial hypercholesterolemia comes with higher risk of aortic stenosis compared to the general population, according to a Norwegian registry study. Whether early initiation of LDL cholesterol-lowering therapy could prevent aortic stenosis might b...

see more →

Patient Education  5 results see all →